A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
National Cancer Institute, Naples
University of Pittsburgh
AstraZeneca
Coherus Oncology, Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Memorial Sloan Kettering Cancer Center
Novartis
City of Hope Medical Center
InSilico Medicine Hong Kong Limited
University Health Network, Toronto
AstraZeneca
University of California, San Diego
BeiGene
Eli Lilly and Company
ALX Oncology Inc.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.